Cargando…
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding m...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023812/ https://www.ncbi.nlm.nih.gov/pubmed/32061264 http://dx.doi.org/10.1186/s12883-020-01633-3 |
_version_ | 1783498333501784064 |
---|---|
author | Deng, Hong Li, Gai-gai Nie, Hao Feng, Yang-yang Guo, Guang-yu Guo, Wen-liang Tang, Zhou-ping |
author_facet | Deng, Hong Li, Gai-gai Nie, Hao Feng, Yang-yang Guo, Guang-yu Guo, Wen-liang Tang, Zhou-ping |
author_sort | Deng, Hong |
collection | PubMed |
description | BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibody (CGRP mAb) for the preventive treatment of episodic migraine, and provide high-quality clinical evidence for migraine therapy. METHODS: A systematic electronic database search was conducted to identify the potentially relevant studies. Two independent authors performed data extraction and quality appraisal. Mean difference (MD) and risk ratio (RR) were pooled for continuous and dichotomous data, respectively. The significance levels, weighted effect sizes and homogeneity of variance were calculated. RESULTS: Eleven high-quality randomized control trials that collectively included 4402 patients were included in this meta-analysis. Compared to placebo group, CGRP mAb therapy resulted in a reduction of monthly migraine days [weighted mean difference (WMD) = − 1.44, 95% CI = (− 1.68,− 1.19)] and acute migraine-specific medication days [WMD = − 1.28, 95% CI = (− 1.66,− 0.90)], with an improvement in 50% responder rate [RR = 1.51, 95% CI = (1.37,1.66)]. In addition, the adverse events (AEs) and treatment withdrawal rates due to AEs were not significantly different between CGRP mAb and placebo groups. Similar efficacy and safety results were obtained for erenumab, fremanezumab, and galcanezumab in subgroup analysis. CONCLUSIONS: The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine. |
format | Online Article Text |
id | pubmed-7023812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70238122020-02-20 Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis Deng, Hong Li, Gai-gai Nie, Hao Feng, Yang-yang Guo, Guang-yu Guo, Wen-liang Tang, Zhou-ping BMC Neurol Review BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibody (CGRP mAb) for the preventive treatment of episodic migraine, and provide high-quality clinical evidence for migraine therapy. METHODS: A systematic electronic database search was conducted to identify the potentially relevant studies. Two independent authors performed data extraction and quality appraisal. Mean difference (MD) and risk ratio (RR) were pooled for continuous and dichotomous data, respectively. The significance levels, weighted effect sizes and homogeneity of variance were calculated. RESULTS: Eleven high-quality randomized control trials that collectively included 4402 patients were included in this meta-analysis. Compared to placebo group, CGRP mAb therapy resulted in a reduction of monthly migraine days [weighted mean difference (WMD) = − 1.44, 95% CI = (− 1.68,− 1.19)] and acute migraine-specific medication days [WMD = − 1.28, 95% CI = (− 1.66,− 0.90)], with an improvement in 50% responder rate [RR = 1.51, 95% CI = (1.37,1.66)]. In addition, the adverse events (AEs) and treatment withdrawal rates due to AEs were not significantly different between CGRP mAb and placebo groups. Similar efficacy and safety results were obtained for erenumab, fremanezumab, and galcanezumab in subgroup analysis. CONCLUSIONS: The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine. BioMed Central 2020-02-15 /pmc/articles/PMC7023812/ /pubmed/32061264 http://dx.doi.org/10.1186/s12883-020-01633-3 Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Deng, Hong Li, Gai-gai Nie, Hao Feng, Yang-yang Guo, Guang-yu Guo, Wen-liang Tang, Zhou-ping Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
title | Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
title_full | Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
title_fullStr | Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
title_full_unstemmed | Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
title_short | Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
title_sort | efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023812/ https://www.ncbi.nlm.nih.gov/pubmed/32061264 http://dx.doi.org/10.1186/s12883-020-01633-3 |
work_keys_str_mv | AT denghong efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis AT ligaigai efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis AT niehao efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis AT fengyangyang efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis AT guoguangyu efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis AT guowenliang efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis AT tangzhouping efficacyandsafetyofcalcitoningenerelatedpeptidebindingmonoclonalantibodiesforthepreventivetreatmentofepisodicmigraineanupdatedsystematicreviewandmetaanalysis |